

The ABCs of Myodesopsia: etiology and Management of age-related Vitreous Floaters

Ross Kennamer-Chapman MD

Georgia Retina

- Vitreous Basics
- Composed of water, collagen, and hyaluronic acid*
 - + minor GAGs including chondroitin sulfate
- Central vs. cortical vitreous
- Certain areas of cortical vitreous are firmly adherent
- Age-related changes in the vitreous
- Increase in liquid volume over time
 - Vitreous Syneresis
 - Vitreous Synchysis
 - Lacunae
 - Bursa
- Posterior vitreous detachment
- Clear gel in youth → fibrous structure with lacunae in adulthood
- Changes in the Vitreous with Age
- Formation of vitreous floaters
- Free radicals → Changes in collagen or the conformation and association of hyaluronic acid with collagen → crosslinking and aggregation of fibrils into bundles
- Posterior Vitreous Detachment (PVD)
- A separation between the ILM and the cortical vitreous
- Increasing incidence with age
- Anomalous PVD is due to abnormal vitreoretinal adherence
- Weakening in the posterior cortical vitreous (in the perimacular region) → liquid vitreous enters the retrohyaloid space → posterior vitreous detachment progresses

- Symptoms of vitreous opacities
- Dark spots, shadows, webs, "mobile smudge" etc.
- Move with intravitreal currents and with inertia of the vitreous body related to head or eye movements
- Symptoms are most noticeable when
 - Floaters are centrally located
 - Monochrome background
- Other etiologies of vitreous floaters to remember
- Vitreous hemorrhage
- Uveitis
- Amyloidosis
- Ocular lymphoma
- Visual Impact of Floaters
- Straylight
- Light scattering
- Contrast sensitivity
 - Incidence of Floaters
- Webb et al 2013 demonstrated that up to 76% of people see floaters and that 33% of people are at least moderately bothered by them
 - Non-clinical data set
 - Moderate/Severe floaters refer to range between "They are annoying, but don't interfere with being able to see things" (3) to "They are a serious problem, making it hard to see" (5)
 - Myopes reported more significant symptoms from floaters
 - Age had no significant effect on the severity of floaters
 - Utility Value of Floaters
- Wagle et al. 2011 assessed the utility values associated with vitreous floaters

- Patients were enrolled who presented with a chief complaint of floaters
- Time trade off (TTO)
 - Measures number of years of remaining life patient would be willing to trade
 - Patients were willing to trade 1.1 of every 10 remaining years of life
- Standard gamble (SG)
 - Assesses patient tolerance of risk for hypothetical technology that would return patient to “perfect” health state
 - Patients tolerated 11% risk of death and 7% risk of blindness
- When to Intervene?
- Symptomatic vitreous opacities (SVOs) may be defined as floaters that cause symptoms for a minimum of 3 months and are severe enough for the patient to explore therapeutic options
- No universal agreed upon criteria for when to intervene for SVOs
- What are the options for management?
- Observation
- Pharmacologic*
- YAG Vitreolysis
- Pars plana vitrectomy
- Observation
- Rule out anomalous PVD (APVD)
- Patients are often told that a combination of “settling” of vitreous opacities and neuro-adaptation will alleviate symptoms
- Lack of good data regarding patient outcomes
- Wagle et al. 2011 found no difference in utility values associated with acute vs. chronic floaters
- PHARMACOLOGIC*
- Pharmacodilation

- Preliminary, unpublished data from IOFS website indicates some patients given 0.01% atropine have a decrease in symptoms from vitreous floaters
- PHARMACOLOGIC*
- Ankamah et al 2021 gave patient daily supplement* in RCT with **61** total patients
 - Results:
 - Reduced visual discomfort
 - Reduced floater area measurements
 - Improved photopic contrast sensitivity
 - PHARMACOLOGIC*
- Ankamah et al 2021 gave patient daily supplement* in RCT with **61** total patients
 - Results:
 - Reduced visual discomfort
 - Reduced floater area measurements
 - Improved photopic contrast sensitivity
 - PHARMACOLOGIC*
- Ankamah et al 2021 gave patient daily supplement* in RCT with **61** total patients
 - Results:
 - Reduced visual discomfort
 - Reduced floater area measurements
 - Improved photopic contrast sensitivity
 - YAG Vitreolysis
- YAG Vitreolysis
- Closed eye procedure: lyse fibers and break up aggregates → displace out of visual axis
- Pros:
 - Closed eye
 - In office

- Time
- Cons:
 - Limited by floater location, possibly by type of floater
 - Highly variable success rates
 - Range from 0 to 100%
 - Risks of complications
- Evidence for YAG Vitreolysis
- Shah et al. 2017 published an RCT of YAG vs. sham YAG for SVOs
 - 52 patients, 36 of which received YAG vitreolysis
 - Strict inclusion criteria:
 - Symptomatic Weiss ring floater secondary to PVD
 - Symptoms >6 months
 - PVD documented on exam, OCT, and B-scan
 - Floater located ≥ 3 mm from the retina, ≥ 5 mm from the posterior lens capsule
 - Results:
 - Reassessed at 6 months
 - 54% YAG compared to 9% sham reported improvement in floater visual disturbance
 - 53% YAG reported significant or complete resolution compared to 0% in sham group
- Risks of YAG
- Case series/reports with numerous complications
 - Retinal hemorrhages
 - Retinal breaks/detachments
 - Vein occlusion
 - Opacities in crystalline lens

- Possibly low(er) risk if done safely with thorough pre-procedure evaluation
- Shah et al reported a mean of 218 laser shots with an average total power of 1316 mJ
 - Strict inclusion criteria
 - No complications
- Complications from YAG Vitreolysis
- Shields et al. 2021 published a case series of complications due to YAG floaterectomy
- Vitrectomy for Vitreous Floaters
- Near complete (+/-) removal of the vitreous
- Current techniques have lower risk and faster recovery associated with smaller gauge vitrectomy
- Pros:
 - More complete removal
 - Effective for large individual floaters and diffuse floaters
- Cons
 - Requires a trip to the OR
 - Carries the risk of vitrectomy surgery
 - Cataract formation
 - Surgical Techniques
- Limited vs. Complete Vitrectomy
 - "Vitreous Opacity Vitrectomy (VOV)" coined by Morris et al 2022
 - 27 gauge
 - High cut rate, low suction rate
 - Avoid excessive attempts at PVD induction
 - Topical anesthesia
 - Lin et al 2017 published a case series

- 27 gauge, Proparacaine x 3 q5minutes, 10-15 minute operating time
- Patient Satisfaction after Vitrectomy For Vitreous Floaters
- Mason et 2014 performed 25 gauge sutureless vitrectomy on 168 eyes (143 patients) for floaters
 - Results
 - 96% of patients satisfied
 - 94% of patients reported complete success
 - Transient Complications:
 - 7% of patients with intraoperative break*
 - 2 patients developed vitreous hemorrhage
 - 1 patient developed CME
- Vitrectomy Complications
- Jackson et al 2013 collected 8 years of surgical data from NHS, over 11,000 surgeries
 - Overall, 7.8% risk of any INTRAoperative complications
 - A report by the AAO describes rates of postoperative complications (Recchia et al 2010)
 - 0.03 to 0.07% risk of endophthalmitis
 - 1.8 to 25% postoperative hypotony (typically transient)
 - 10% risk of cystoid macular edema
 - My ideal “floaterectomy” patient
- Anatomic:
 - +PVD
 - +Pseudophakic
 - No high myopia/lattice degeneration
- Patient factors
 - Floaters are persistent, visually significant and are impairing quality of life

- Realistic expectations
- Understanding of risk/benefit of surgery
- In Summary
- Vitreous opacities are common and often overlooked.
- There is evidence that treatment for select patients with YAG vitreolysis may alleviate symptoms, but there are significant questions regarding the risk/benefit profile.
- Pars plana vitrectomy has a high success rate for the treatment of floaters, but is not without risks. It is reasonable to consider in select patients.